Risk of exogenous estrogen therapy and endometrial cancer.


Journal Article

A retrospective study was carried out on 431 patients with endometrial cancer and 431 control subjects matched as to age, race, and parity. They were seen at Duke University Medical Center from 1940 to 1975. The study was performed in order to evaluate the risk of exogenous estrogen therapy and the development of adenocarcinoma of the endometrium. The overall risk was 2.38, with certain subgroups demonstrating different degrees of risk. Increased risk was associated with estrogen therapy of longer than 5 years' duration in white patients. The risk also was confined to Stage I, grade 1 lesions and more superficial myometrial invasion. Five-year survival for patients who used estrogen replacement and had Stage I, grade 1 lesions was 94.7%. The risks associated with exogenous estrogens are real but should be considered in a risk/benefit context when prescribing for the needs of an individual patient.

Full Text

Duke Authors

Cited Authors

  • Jelovsek, FR; Hammond, CB; Woodard, BH; Draffin, R; Lee, KL; Creasman, WT; Parker, RT

Published Date

  • May 1, 1980

Published In

Volume / Issue

  • 137 / 1

Start / End Page

  • 85 - 91

PubMed ID

  • 7369293

Pubmed Central ID

  • 7369293

International Standard Serial Number (ISSN)

  • 0002-9378

Digital Object Identifier (DOI)

  • 10.1016/0002-9378(80)90390-7


  • eng

Conference Location

  • United States